Skip to main content
Erschienen in: Neurosurgical Review 3/2012

01.07.2012 | Original Article

Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies

verfasst von: Georg Widhalm, Georgi Minchev, Adelheid Woehrer, Matthias Preusser, Barbara Kiesel, Julia Furtner, Aygül Mert, Antonio Di Ieva, Boguslaw Tomanek, Daniela Prayer, Christine Marosi, Johannes A. Hainfellner, Engelbert Knosp, Stefan Wolfsberger

Erschienen in: Neurosurgical Review | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Stereotactic biopsies represent a routine neurosurgical procedure for the diagnosis of intracranial lymphomas and selected diffusely infiltrating gliomas. Acquisition of tissue samples that do not allow correct tumor typing and grading is, however, not uncommon. Five-aminolevulinic acid (5-ALA) has been shown to accumulate in malignant tumor tissue. The aim of this study was to prospectively investigate the clinical usability of 5-ALA for intraoperative detection of representative tissue in stereotactic tumor biopsies. Fifty consecutive patients underwent frameless stereotactic biopsy for a suspected brain tumor. 5-ALA was administered 4 h before anesthesia. Serial biopsy samples were obtained and intraoperatively checked for 5-ALA fluorescence (strong, vague, or none) using a modified neurosurgical microscope. All samples were examined for the presence of representative tumor tissue according to neuroimaging (MRI, positron emission tomography, and/or chemical shift imaging) and histopathological parameters. Visible 5-ALA fluorescence was observed in 43/50 patients (strong in 39 and vague fluorescence in four cases). At biopsy target, 52/53 samples of glioblastomas, 9/10 samples of gliomas grade III, and 14/16 samples of lymphomas revealed strong 5-ALA fluorescence. Samples with strong 5-ALA fluorescence were only observed at, but not outside the biopsy target. All tissue samples with strong 5-ALA fluorescence were representative according to our neuroimaging and histopathological criteria (positive predictive value of 100%). Our data indicate that strong 5-ALA fluorescence is a reliable and immediately available intraoperative marker of representative tumor tissue of malignant gliomas and intracranial lymphomas in stereotactic biopsies. Thereby, the application of 5-ALA in stereotactic brain tumor biopsies may in future reduce costs for operating room and neuropathology and may decrease procedure-related morbidity.
Literatur
1.
Zurück zum Zitat Aker FV, Hakan T, Karadereler S, Erkan M (2005) Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimens. Neuropathology 25(3):207–213PubMedCrossRef Aker FV, Hakan T, Karadereler S, Erkan M (2005) Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimens. Neuropathology 25(3):207–213PubMedCrossRef
2.
Zurück zum Zitat Calisaneller T, Ozdemir O, Ozger O, Ozen O, Kiyici H, Caner H, Altinors N (2008) The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions. Turk Neurosurg 18(1):17–22PubMed Calisaneller T, Ozdemir O, Ozger O, Ozen O, Kiyici H, Caner H, Altinors N (2008) The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions. Turk Neurosurg 18(1):17–22PubMed
3.
Zurück zum Zitat Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ (2008) Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 150(1):23–29CrossRef Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ (2008) Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 150(1):23–29CrossRef
4.
Zurück zum Zitat Dammers R, Schouten JW, Haitsma IK, Vincent AJ, Kros JM, Dirven CM (2010) Towards improving the safety and diagnostic yield of stereotactic biopsy in a single centre. Acta Neurochir (Wien) 152(11):1915–1921CrossRef Dammers R, Schouten JW, Haitsma IK, Vincent AJ, Kros JM, Dirven CM (2010) Towards improving the safety and diagnostic yield of stereotactic biopsy in a single centre. Acta Neurochir (Wien) 152(11):1915–1921CrossRef
5.
Zurück zum Zitat Dickerman RD, Mittler MA, Morgan JT (2005) Stereotactic brain biopsies and operative complications: technique to further decrease risks. Acta Neurochir (Wien) 147(8):911–912CrossRef Dickerman RD, Mittler MA, Morgan JT (2005) Stereotactic brain biopsies and operative complications: technique to further decrease risks. Acta Neurochir (Wien) 147(8):911–912CrossRef
6.
Zurück zum Zitat Dorward NL, Paleologos TS, Alberti O, Thomas DG (2002) The advantages of frameless stereotactic biopsy over frame-based biopsy. Br J Neurosurg 16(2):110–118PubMedCrossRef Dorward NL, Paleologos TS, Alberti O, Thomas DG (2002) The advantages of frameless stereotactic biopsy over frame-based biopsy. Br J Neurosurg 16(2):110–118PubMedCrossRef
7.
Zurück zum Zitat Eljamel MS (2009) Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. Clin Neurosurg 56:93–97PubMed Eljamel MS (2009) Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. Clin Neurosurg 56:93–97PubMed
8.
Zurück zum Zitat Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD (2001) Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 94(4):545–551PubMedCrossRef Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD (2001) Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 94(4):545–551PubMedCrossRef
9.
Zurück zum Zitat Gralla J, Nimsky C, Buchfelder M, Fahlbusch R, Ganslandt O (2003) Frameless stereotactic brain biopsy procedures using the Stealth Station: indications, accuracy and results. Zentralbl Neurochir 64(4):166–170PubMedCrossRef Gralla J, Nimsky C, Buchfelder M, Fahlbusch R, Ganslandt O (2003) Frameless stereotactic brain biopsy procedures using the Stealth Station: indications, accuracy and results. Zentralbl Neurochir 64(4):166–170PubMedCrossRef
10.
Zurück zum Zitat Grossman R, Sadetzki S, Spiegelmann R, Ram Z (2005) Haemorrhagic complications and the incidence of asymptomatic bleeding associated with stereotactic brain biopsies. Acta Neurochir (Wien) 147(6):627–631CrossRef Grossman R, Sadetzki S, Spiegelmann R, Ram Z (2005) Haemorrhagic complications and the incidence of asymptomatic bleeding associated with stereotactic brain biopsies. Acta Neurochir (Wien) 147(6):627–631CrossRef
11.
Zurück zum Zitat Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82(9):1749–1755PubMedCrossRef Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82(9):1749–1755PubMedCrossRef
12.
Zurück zum Zitat Hall WA, Truwit CL (2008) Intraoperative MR-guided neurosurgery. J Magn Reson Imaging 27(2):368–375PubMedCrossRef Hall WA, Truwit CL (2008) Intraoperative MR-guided neurosurgery. J Magn Reson Imaging 27(2):368–375PubMedCrossRef
13.
Zurück zum Zitat Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H (2008) 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institution. Swiss Med Wkly 138(11–12):180–185PubMed Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H (2008) 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institution. Swiss Med Wkly 138(11–12):180–185PubMed
14.
Zurück zum Zitat Heper AO, Erden E, Savas A, Ceyhan K, Erden I, Akyar S, Kanpolat Y (2005) An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: a prospective clinicopathologic study. Surg Neurol 64(Suppl 2):S82–88PubMedCrossRef Heper AO, Erden E, Savas A, Ceyhan K, Erden I, Akyar S, Kanpolat Y (2005) An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: a prospective clinicopathologic study. Surg Neurol 64(Suppl 2):S82–88PubMedCrossRef
15.
Zurück zum Zitat Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H (2008) Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 86(5):300–307PubMedCrossRef Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H (2008) Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 86(5):300–307PubMedCrossRef
16.
Zurück zum Zitat Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3(3):193–200PubMed Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3(3):193–200PubMed
17.
Zurück zum Zitat Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK (2006) Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 23(2):71–75PubMedCrossRef Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK (2006) Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 23(2):71–75PubMedCrossRef
18.
Zurück zum Zitat Kelly PJ (1991) Tumor stereotaxis. WB Saunders, Philadelphia Kelly PJ (1991) Tumor stereotaxis. WB Saunders, Philadelphia
19.
Zurück zum Zitat Kondziolka D, Firlik AD, Lunsford LD (1998) Complications of stereotactic brain surgery. Neurol Clin 16(1):35–54PubMedCrossRef Kondziolka D, Firlik AD, Lunsford LD (1998) Complications of stereotactic brain surgery. Neurol Clin 16(1):35–54PubMedCrossRef
20.
Zurück zum Zitat Krieger MD, Chandrasoma PT, Zee CS, Apuzzo ML (1998) Role of stereotactic biopsy in the diagnosis and management of brain tumors. Semin Surg Oncol 14(1):13–25PubMedCrossRef Krieger MD, Chandrasoma PT, Zee CS, Apuzzo ML (1998) Role of stereotactic biopsy in the diagnosis and management of brain tumors. Semin Surg Oncol 14(1):13–25PubMedCrossRef
21.
Zurück zum Zitat Kulkarni AV, Guha A, Lozano A, Bernstein M (1998) Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg 89(1):31–35PubMedCrossRef Kulkarni AV, Guha A, Lozano A, Bernstein M (1998) Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg 89(1):31–35PubMedCrossRef
22.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of the central nervous system. IARC, Lyon Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of the central nervous system. IARC, Lyon
23.
Zurück zum Zitat Lunsford LD, Niranjan A, Khan AA, Kondziolka D (2008) Establishing a benchmark for complications using frame-based stereotactic surgery. Stereotact Funct Neurosurg 86(5):278–287PubMedCrossRef Lunsford LD, Niranjan A, Khan AA, Kondziolka D (2008) Establishing a benchmark for complications using frame-based stereotactic surgery. Stereotact Funct Neurosurg 86(5):278–287PubMedCrossRef
24.
Zurück zum Zitat Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, Nakamura R, Iseki H, Hori T, Takakura K (2008) Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg 51(5):275–279PubMedCrossRef Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, Nakamura R, Iseki H, Hori T, Takakura K (2008) Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg 51(5):275–279PubMedCrossRef
25.
Zurück zum Zitat Pirotte B, Goldman S, David P, Wikler D, Damhaut P, Vandesteene A, Salmon L, Brotchi J, Levivier M (1997) Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir Suppl 68:133–138PubMed Pirotte B, Goldman S, David P, Wikler D, Damhaut P, Vandesteene A, Salmon L, Brotchi J, Levivier M (1997) Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir Suppl 68:133–138PubMed
26.
Zurück zum Zitat Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101(3):476–483PubMedCrossRef Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101(3):476–483PubMedCrossRef
27.
Zurück zum Zitat Potzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S (2007) [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84(3):305–314PubMedCrossRef Potzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S (2007) [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84(3):305–314PubMedCrossRef
28.
Zurück zum Zitat Sawin PD, Hitchon PW, Follett KA, Torner JC (1998) Computed imaging-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. Surg Neurol 49(6):640–649PubMedCrossRef Sawin PD, Hitchon PW, Follett KA, Torner JC (1998) Computed imaging-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. Surg Neurol 49(6):640–649PubMedCrossRef
29.
Zurück zum Zitat Shooman D, Belli A, Grundy PL (2010) Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. J Neurosurg 113(2):170–178PubMedCrossRef Shooman D, Belli A, Grundy PL (2010) Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. J Neurosurg 113(2):170–178PubMedCrossRef
30.
Zurück zum Zitat Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93(6):1003–1013PubMedCrossRef Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93(6):1003–1013PubMedCrossRef
31.
Zurück zum Zitat Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401PubMedCrossRef Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401PubMedCrossRef
32.
Zurück zum Zitat Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ (1998) Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 140(10):995–1000CrossRef Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ (1998) Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 140(10):995–1000CrossRef
33.
Zurück zum Zitat Tilgner J, Herr M, Ostertag C, Volk B (2005) Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis—influence of clinical factors. Neurosurgery 56(2):257–265, discussion 257–265PubMedCrossRef Tilgner J, Herr M, Ostertag C, Volk B (2005) Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis—influence of clinical factors. Neurosurgery 56(2):257–265, discussion 257–265PubMedCrossRef
34.
Zurück zum Zitat Widhalm G, Krssak M, Minchev G, Wohrer A, Traub-Weidinger T, Czech T, Asenbaum S, Marosi C, Knosp E, Hainfellner JA, Prayer D, Wolfsberger S (2011) Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. J Neurol Neurosurg Psychiatry 82(5):512–20PubMedCrossRef Widhalm G, Krssak M, Minchev G, Wohrer A, Traub-Weidinger T, Czech T, Asenbaum S, Marosi C, Knosp E, Hainfellner JA, Prayer D, Wolfsberger S (2011) Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. J Neurol Neurosurg Psychiatry 82(5):512–20PubMedCrossRef
35.
Zurück zum Zitat Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E (2010) 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 116(6):1545–1552PubMedCrossRef Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E (2010) 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 116(6):1545–1552PubMedCrossRef
36.
Zurück zum Zitat Wolfsberger S, Rossler K, Regatschnig R, Ungersbock K (2002) Anatomical landmarks for image registration in frameless stereotactic neuronavigation. Neurosurg Rev 25(1–2):68–72PubMedCrossRef Wolfsberger S, Rossler K, Regatschnig R, Ungersbock K (2002) Anatomical landmarks for image registration in frameless stereotactic neuronavigation. Neurosurg Rev 25(1–2):68–72PubMedCrossRef
37.
Zurück zum Zitat Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD (2005) Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res 27(4):358–362PubMedCrossRef Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD (2005) Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res 27(4):358–362PubMedCrossRef
38.
Zurück zum Zitat Zoeller GK, Benveniste RJ, Landy H, Morcos JJ, Jagid J (2009) Outcomes and management strategies after nondiagnostic stereotactic biopsies of brain lesions. Stereotact Funct Neurosurg 87(3):174–181PubMedCrossRef Zoeller GK, Benveniste RJ, Landy H, Morcos JJ, Jagid J (2009) Outcomes and management strategies after nondiagnostic stereotactic biopsies of brain lesions. Stereotact Funct Neurosurg 87(3):174–181PubMedCrossRef
Metadaten
Titel
Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies
verfasst von
Georg Widhalm
Georgi Minchev
Adelheid Woehrer
Matthias Preusser
Barbara Kiesel
Julia Furtner
Aygül Mert
Antonio Di Ieva
Boguslaw Tomanek
Daniela Prayer
Christine Marosi
Johannes A. Hainfellner
Engelbert Knosp
Stefan Wolfsberger
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Neurosurgical Review / Ausgabe 3/2012
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-012-0374-5

Weitere Artikel der Ausgabe 3/2012

Neurosurgical Review 3/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.